Product Details
Keypath p16 Immunoassay Test Kit(ICC)
Introduction
p16 Antibody Reagent is an important marker for cervical cancer
screening and diagnosis.
The p16INK4a detection technology is a new detection method joint recommended
by CAP and ASCCP.
There’s close relationship between p16 and cervical cancer.
Persistent HPV infection produces viral oncogenic protein E7, which
binds to host cell PRB, releases transcription factor E2F,
interferes with the cell cycle, and causes cells to continue to
differentiate and develop precancerous lesions.
Principle
Based on the principle of specific binding between immunological
antigen and antibody, the antibody is combined with enzyme-labeled
chromogenic system to form a complex, and enzyme substrate
(chromogenic agent) is added to make it chromogenic to locate and
characterize the antigen to be detected. The location of cell
staining is nucleus/cytoplasm.
P16 is one of the cell cycle regulatory proteins, also known as
"mitosis inhibitor". Its role is to competitively bind CDK4/6 with
cyclin D, and stop
the process of cells from G1 to S, thus negatively regulating
mitosis. In tumor cells, gene mutation or deletion often leads to
the increase of p16
expression, but the cell cycle can not be regulated. This antibody
is mainly used in tumor research.
Advantages
- The detection is with statistical significance by improved
sensitivity and specificity.
- Reduce workload, improve image reading efficiency, and reduce
missed diagnosis rate.
- Reduce referral rates for colposcopy and reduce overtreatment.
- Whether p16 staining is positive or not indicates transient or
persistent HPV infection, and p16-positive cells prompt the
cytology doctor to review the liquid-based results.
Packaging
- 25 tests/kit ,50 tests/kit ,100 tests/kit
Company Profile
Shenzhen Kisshealh Biotechnology Co., Ltd., located in the Pingshan
District, Shenzhen, P.R. China. is a diagnostics company focused on
the development and manufacture of IVD tests at the Point-of-Care
with highly innovative proprietary technology.
We focused on the emerging markets of in vitro pathological
diagnosis and immunodiagnosis. We developed, manufactured and
successfully launched the in vitro immunodiagnosis platform for
cancer and the POCT for infectious, genetic and chronic diseases.
<span style="color: rgb(33, 33, 33); text-transform: none;
text-indent: 0px; letter-spacing: normal;" initial;"="" initial;=""
0px;="" normal;="" 255);="" 255,="" rgb(255,="" 2;=""
!important;="" inline="" none;="" 600;="" 14px;="" sans-serif;=""
arial,="" roboto,="" w3",="" gb="" sans="" "hiragino="" gb",=""
hei",="" micro="" "wenquanyi="" sans",="" "droid="" arimo,=""
freesans,="" yahei",="" "microsoft="" helvetica,="" grande",=""
"lucida="" ui",="" segoe="">At Kissh we work every day to shape
the future of in-vitro diagnostic testing. And our people are our
best asset, the reason for our track record and our strength while
we are moving forward. We live by our fundamental values and
incorporate them in everything that we do. Our best asset is ‘Step
Forward Every Second’